




Instance: composition-en-e904990c0daca9f90faf79e88bc809b4
InstanceOf: CompositionUvEpi
Title: "Composition for orladeyo Package Leaflet"
Description:  "Composition for orladeyo Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp1199ab3caf442fe956158c92418d9ae7)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - orladeyo"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Orladeyo is and what it is used for  </li>
<li>What you need to know before you take Orladeyo </li>
<li>How to take Orladeyo </li>
<li>Possible side effects  </li>
<li>How to store Orladeyo  </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What orladeyo is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What orladeyo is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Orladeyo is a medicine that contains the active substance berotralstat. It is used to prevent 
angioedema attacks in adults, and adolescents aged from 12 years with hereditary angioedema.  </p>
<p>What hereditary angioedema is </p>
<p>Hereditary angioedema is a condition that often runs in families. It can limit your daily activity by 
causing attacks of swelling and pain in different parts of your body including: 
* hands and feet 
* face, eyelids, lips or tongue 
* voice-box (larynx), which may make breathing difficult 
* genitals 
* stomach and intestines </p>
<p>How Orladeyo works </p>
<p>In hereditary angioedema your blood does not have enough of a protein called C1 inhibitor, or the 
protein does not work properly. This leads to too much of the enzyme plasma kallikrein, which in turn 
increases the levels of bradykinin in your bloodstream. Too much bradykinin leads to symptoms of 
hereditary angioedema. Berotralstat, the active substance in Orladeyo, blocks the activity of plasma 
kallikrein and so reduces bradykinin. This prevents the swelling and pain that hereditary angioedema 
can cause. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take orladeyo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take orladeyo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Orladeyo </p>
<ul>
<li>if you are allergic to berotralstat or any of the other ingredients of this medicine (listed in 
section 6) </li>
</ul>
<p>Warnings and precautions </p>
<p>Talk to your doctor or pharmacist before taking Orladeyo if you: 
* have moderate or severely reduced liver function which can increase blood levels of berotralstat 
* have severely reduced kidney function 
* are at risk for a certain heartbeat abnormality, known as QT prolongation </p>
<p>Treat a hereditary angioedema attack with your regular rescue medicine without taking additional 
doses of Orladeyo. It is not known if Orladeyo works for immediate treatment of attacks of hereditary 
angioedema. </p>
<p>Children and adolescents </p>
<p>Orladeyo is not recommended in children under 12 years. This is because it has not been studied in 
this age group. 
Orladeyo has not been studied in adolescents weighing less than 40 kg.  </p>
<p>Other medicines and Orladeyo </p>
<p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other 
medicines. </p>
<p>Particularly, tell your doctor before taking Orladeyo if you are using: 
* thioridazine or pimozide, medicines to treat mental disorders 
* amlodipine, a medicine to treat high blood pressure or a type of chest pain called angina<br />
<em> ciclosporin, a medicine to suppress the immune system, treat severe skin diseases and severe 
eye or joint inflammation 
* dabigatran, a medicine to prevent blood clotting 
* rifampicin: a medicine to treat tuberculosis or certain other infections 
* desipramine, St. John s wort and other medicines to treat depression called tricyclic 
antidepressants 
* dextromethorphan, a cough-relieving medicine<br />
</em> digoxin, a medicine to treat heart problems and irregular heartbeat 
* fentanyl, a strong painkiller 
* midazolam, a medicine to treat sleeping disorders and for anaesthesia 
* tolbutamide, a medicine to reduce blood sugar 
* oral contraceptives, medicines used for birth control </p>
<p>Pregnancy and breast-feeding </p>
<p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask 
your doctor or pharmacist for advice before taking this medicine. </p>
<p>There is limited information on the use of Orladeyo during pregnancy and breast-feeding. As a 
precaution, it is preferable to avoid the use of Orladeyo during pregnancy and breast-feeding. Your 
doctor will discuss with you the risks and benefits of taking this medicine. </p>
<p>Women of childbearing potential must use effective contraception during treatment and for at least 
1 month following the last dose. Orladeyo is not recommended in women of childbearing potential not 
using contraception. </p>
<p>Driving and using machines </p>
<p>Orladeyo has no or negligible influence on the ability to drive and use machines. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take orladeyo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take orladeyo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. </p>
<p>The recommended dose is 
The recommended dose for adults and adolescents from 12 years weighing   40 kg is one capsule once 
daily. </p>
<p>Orladeyo is not recommended in patients with moderate or severely reduced liver function. As a 
precautionary measure, this also applies to patients on dialysis. </p>
<p>Method of administration  </p>
<p>Take the capsule with food and one glass of water at the same time each day. This can be at any time 
of the day. </p>
<p>If you take more Orladeyo than you should </p>
<p>Contact your doctor immediately if this occurs. </p>
<p>If you forget to take Orladeyo </p>
<p>Do not take a double dose to make up for a forgotten capsule. Take a missed dose as soon as you 
remember; however, do not take more than one dose per day. </p>
<p>If you stop taking Orladeyo </p>
<p>It is important to take this medicine on a regular basis and for as long as your doctor prescribes it. 
Do not stop taking it without approval from your doctor. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Side effects can occur with the following frequencies: 
Very common, may affect more than 1 in 10 people 
* headache 
* stomach pain, including abdominal (belly) discomfort, abdominal tenderness 
* diarrhoea and frequent bowel movements </p>
<p>Common, may affect up to 1 in 10 people 
* vomiting 
* heartburn 
* wind 
* blood tests showing increased levels of liver enzymes called ALT and AST 
* rash </p>
<p>Reporting of side effects </p>
<p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects, you can help provide more information on the safety 
of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store orladeyo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store orladeyo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP. The 
expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Orladeyo contains </p>
<ul>
<li>The active substance is berotralstat. Each capsule contains 150 mg berotralstat (as 
dihydrochloride). </li>
<li>
<p>The other ingredients are:</p>
</li>
<li>
<p>starch, pregelatinised, crospovidone (type A), silica, colloidal anhydrous, magnesium 
stearate, gelatin, titanium dioxide (E 171) </p>
</li>
<li>colourants: indigo carmine (E 132), black iron oxide (E 172), red iron oxide (E 172) </li>
<li>edible printing ink: black iron oxide (E 172), potassium hydroxide, shellac, propylene 
glycol (E 1520) </li>
</ul>
<p>What Orladeyo looks like and contents of the pack </p>
<p>Orladeyo capsules have a white opaque body imprinted with  150  and light blue opaque cap 
imprinted with  BCX  (19.4 mm   6.9 mm). They are packed in plastic/aluminium blisters in a carton 
with 7 capsules per blister. </p>
<p>Pack size: 28 or 98 hard capsules </p>
<p>Marketing Authorisation Holder and Manufacturer </p>
<ul>
<li>
<p>Marketing Authorisation Holder 
BioCryst Ireland Limited 
Block 4, Harcourt Centre, Harcourt Road, DUBLIN 2, D02HWIreland  </p>
</li>
<li>
<p>Manufacturer 
Millmount Healthcare Limited<br />
Block-7, City North Business Campus,<br />
Stamullen,<br />
Co. Meath, K32 YDIreland  </p>
</li>
</ul>
<p>This leaflet was last revised in  </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-e904990c0daca9f90faf79e88bc809b4
InstanceOf: CompositionUvEpi
Title: "Composition for orladeyo Package Leaflet"
Description:  "Composition for orladeyo Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp1199ab3caf442fe956158c92418d9ae7)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - orladeyo"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen </p>
<ol>
<li>Virkning og anvendelse  </li>
<li>Det skal du vide, før du begynder at tage Orladeyo </li>
<li>Sådan skal du tage Orladeyo </li>
<li>Bivirkninger  </li>
<li>Opbevaring  </li>
<li>Pakningsstørrelser og yderligere oplysninger </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What orladeyo is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What orladeyo is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Orladeyo er et lægemiddel, der indeholder det aktive stof berotralstat. Det anvendes til forebyggelse 
af angioødem-anfald (hævelse) hos voksne og unge fra 12 år med arveligt angioødem.  </p>
<p>Hvad er arveligt angioødem? </p>
<p>Arveligt angioødem er en medfødt sygdom. Sygdommen kan begrænse dine daglige aktiviteter som 
følge af anfald med hævelse og smerter i forskellige dele af kroppen, herunder: </p>
<ul>
<li>
<p>hænder og fødder </p>
</li>
<li>
<p>ansigt, øjenlåg, læber eller tunge </p>
</li>
<li>
<p>strubehoved, hvilket kan give vejrtrækningsbesvær </p>
</li>
<li>
<p>kønsorganer </p>
</li>
<li>
<p>mave og tarme </p>
</li>
</ul>
<p>Hvordan virker Orladeyo? </p>
<p>Ved arveligt angioødem har blodet ikke nok af det såkaldte C1-hæmmer-protein, eller også fungerer 
proteinet ikke, som det skal. Dette medfører for meget af enzymet plasmakallikrein, som så øger 
niveauet af bradykinin i blodbanen. Ved for meget bradykinin opstår der symptomer på arveligt 
angioødem. Berotralstat, der er det aktive stof i Orladeyo, blokerer for aktiviteten af plasmakallikrein, 
hvorved mængden af bradykinin reduceres. På den måde forebygges hævelsen og smerterne ved 
arveligt angioødem. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take orladeyo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take orladeyo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Orladeyo </p>
<ul>
<li>hvis du er allergisk over for berotralstat eller et af de øvrige indholdsstoffer i Orladeyo (angivet 
i punkt 6). </li>
</ul>
<p>Advarsler og forsigtighedsregler </p>
<p>Kontakt lægen eller apotekspersonalet, før du tager Orladeyo, hvis du: </p>
<ul>
<li>
<p>har moderat eller svært nedsat leverfunktion, da dette kan øge niveauet af berotralstat i blodet </p>
</li>
<li>
<p>har svært nedsat nyrefunktion </p>
</li>
<li>
<p>har risiko for såkaldt QT-forlængelse (en type unormal hjerterytme). </p>
</li>
</ul>
<p>Du skal behandle et anfald af arveligt angioødem med din sædvanlige nødmedicin uden at tage 
yderligere doser af Orladeyo. Det vides ikke, om Orladeyo er egnet til akut behandling af anfald af 
arveligt angioødem. </p>
<p>Børn og unge </p>
<p>Orladeyo anbefales ikke til børn under 12 år, da lægemidlet ikke er undersøgt hos denne aldersgruppe. 
Orladeyo er ikke undersøgt hos unge, der vejer under 40 kg.  </p>
<p>Brug af anden medicin sammen med Orladeyo </p>
<p>Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget 
anden medicin eller planlægger at tage anden medicin. </p>
<p>Før du begynder at tage Orladeyo, er det særligt vigtigt at sige det til lægen, hvis du tager: </p>
<ul>
<li>
<p>thioridazin eller pimozid (mod psykiske lidelser) </p>
</li>
<li>
<p>amlodipin (mod forhøjet blodtryk eller angina pectoris (brystkrampe))  </p>
</li>
<li>
<p>ciclosporin (immundæmpende lægemiddel til behandling af hudsygdomme og alvorlig øjen- eller ledbetændelse) </p>
</li>
<li>
<p>dabigatran (til forebyggelse af blodpropper) </p>
</li>
<li>
<p>rifampicin (mod tuberkulose og visse andre infektioner) </p>
</li>
<li>
<p>desipramin, prikbladet perikon og såkaldte tricykliske antidepressiva (mod depression) </p>
</li>
<li>
<p>dextromethorphan (hostelindrende middel)  </p>
</li>
<li>
<p>digoxin (mod hjerteproblemer, herunder uregelmæssig hjerterytme) </p>
</li>
<li>
<p>fentanyl (et stærkt smertestillende middel) </p>
</li>
<li>
<p>midazolam (et sove- og bedøvelsesmiddel) </p>
</li>
<li>
<p>tolbutamid (til reduktion af blodsukkeret) </p>
</li>
<li>
<p>p-piller (præventionsmiddel). </p>
</li>
</ul>
<p>Graviditet og amning </p>
<p>Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge eller apotekspersonalet til råds, før du tager dette lægemiddel. </p>
<p>Der foreligger kun begrænsede data om brugen af Orladeyo under graviditet og amning. Som 
forsigtighedsforanstaltning anbefales det at undgå anvendelse af Orladeyo under graviditet og amning. 
Din læge vil tale med dig om risici og fordele ved at tage dette lægemiddel. </p>
<p>Kvinder, der kan blive gravide, skal anvende sikker prævention under behandlingen og i mindst 
1 måned efter den sidste dosis. Orladeyo bør ikke anvendes hos kvinder i den fødedygtige alder, der 
ikke bruger prævention. </p>
<p>Trafik- og arbejdssikkerhed </p>
<p>Orladeyo påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene maskiner. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take orladeyo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take orladeyo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Anbefalet dosis 
Den anbefalede dosis til voksne og unge fra 12 år, der vejer ≥ 40 kg, er én kapsel én gang dagligt. </p>
<p>Orladeyo anbefales ikke til patienter med moderat eller svært nedsat leverfunktion. Som 
forsigtighedsforanstaltning gælder dette også patienter i dialyse. </p>
<p>Indgivelsesmåde  </p>
<p>Tag kapslen sammen med mad og et glas vand på samme tidspunkt hver dag. Du kan selv bestemme 
tidspunktet på dagen. </p>
<p>Hvis du har taget for meget Orladeyo </p>
<p>Sig det til lægen med det samme, hvis det sker. </p>
<p>Hvis du har glemt at tage Orladeyo </p>
<p>Du må ikke tage en dobbeltdosis som erstatning for en glemt kapsel. Tag en glemt dosis, så snart du 
kommer i tanker om det (men du må kun tage én dosis om dagen). </p>
<p>Hvis du holder op med at tage Orladeyo </p>
<p>Det er vigtigt at tage dette lægemiddel på regelmæssig vis og i så lang tid, som lægen har ordineret. 
Du må ikke holde op med at tage Orladeyo uden lægens godkendelse. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Bivirkningerne kan optræde med følgende hyppigheder: 
Meget almindelige bivirkninger (kan forekomme hos mere end 1 ud af 10 patienter) </p>
<ul>
<li>
<p>hovedpine </p>
</li>
<li>
<p>mavesmerter, herunder ubehag eller ømhed i maveregionen </p>
</li>
<li>
<p>diarré og hyppig afføring </p>
</li>
</ul>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 patienter) </p>
<ul>
<li>
<p>opkastning </p>
</li>
<li>
<p>halsbrand </p>
</li>
<li>
<p>luft i tarmene </p>
</li>
<li>
<p>forhøjede leverenzymer (ALAT og ASAT) </p>
</li>
<li>
<p>udslæt </p>
</li>
</ul>
<p>Indberetning af bivirkninger </p>
<p>Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store orladeyo"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store orladeyo"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken og blisterpakningen efter EXP. 
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </p>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Orladeyo indeholder: </p>
<ul>
<li>
<p>Aktivt stof: berotralstat. Hver kapsel indeholder 150 mg berotralstat (som dihydrochlorid). </p>
</li>
<li>
<p>Øvrige indholdsstoffer:</p>
</li>
<li>
<p>prægelatineret stivelse, crospovidon (type A), silica, kolloid vandfri, magnesiumstearat, 
gelatine, titandioxid (E171) </p>
</li>
<li>farvestoffer: indigocarmin (E132), sort jernoxid (E172) og rød jernoxid (E172) </li>
<li>spiselig trykfarve: sort jernoxid (E172), kaliumhydroxid, shellac, propylenglycol (E1520) </li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<p>Orladeyo-kapsler har en hvid uigennemsigtig underdel præget med "150" og en lyseblå 
uigennemsigtig overdel præget med "BCX" (19,4 mm × 6,9 mm). Kapslerne er pakket i blisterkort af 
plast/aluminium i en æske med 7 kapsler pr. blisterkort. </p>
<p>Pakningsstørrelser: 28 eller 98 hårde kapsler </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller </p>
<ul>
<li>
<p>Indehaver af markedsføringstilladelsen 
BioCryst Ireland Limited 
Block 4, Harcourt Centre, Harcourt Road, Dublin 2, D02HW77<br />
Irland  </p>
</li>
<li>
<p>Fremstiller 
Millmount Healthcare Limited<br />
Block-7, City North Business Campus,<br />
Stamullen,<br />
Co. Meath, K32 YDIrland  </p>
</li>
</ul>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-e904990c0daca9f90faf79e88bc809b4
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for orladeyo Package Leaflet for language en"
Description: "ePI document Bundle for orladeyo Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-e904990c0daca9f90faf79e88bc809b4"
* entry[0].resource = composition-en-e904990c0daca9f90faf79e88bc809b4

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpe904990c0daca9f90faf79e88bc809b4"
* entry[=].resource = mpe904990c0daca9f90faf79e88bc809b4
                            
                    
Instance: bundlepackageleaflet-da-e904990c0daca9f90faf79e88bc809b4
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for orladeyo Package Leaflet for language da"
Description: "ePI document Bundle for orladeyo Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-e904990c0daca9f90faf79e88bc809b4"
* entry[0].resource = composition-da-e904990c0daca9f90faf79e88bc809b4

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mpe904990c0daca9f90faf79e88bc809b4"
* entry[=].resource = mpe904990c0daca9f90faf79e88bc809b4
                            
                    



Instance: mpe904990c0daca9f90faf79e88bc809b4
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product orladeyo"
Description: "orladeyo"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/21/1544/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in"


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "orladeyo"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: e904990c0daca9f90faf79e88bc809b4ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "orladeyo"

* status = #current
* mode = #working

* title = "List of all ePIs associated with orladeyo"

* subject = Reference(mp1199ab3caf442fe956158c92418d9ae7)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#orladeyo "orladeyo"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-e904990c0daca9f90faf79e88bc809b4) // orladeyo en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-e904990c0daca9f90faf79e88bc809b4) // orladeyo da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-e904990c0daca9f90faf79e88bc809b4
InstanceOf: List

* insert e904990c0daca9f90faf79e88bc809b4ListRuleset
    